Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
MARA rated glofitamab (COLUMVI) A (Strong) before HAS published CT opinion CT21596 on 18 March 2026. The A signal correctly predicted that reimbursement would be granted — HAS concluded SMR
MARA rated ruxolitinib cream (Opzelura) B++ (Marginal) before NICE published TA1140 on 17 March 2026. The B++ signal was driven by three decision-critical domains rated structurally weak: HRQoL data were
Link to the latest MARA Rating Executive SummaryThe MARA Rating for Leqembi (lecanemab) in early Alzheimer’s disease has been affirmed at B++ (Marginal) as of March 2026 following structured committee review. The rating band
NICE: MARA rated targeted-release budesonide (Kinpeygo) A (Strong) before NICE published TA1128 on 4 February 2026. The A grade correctly predicted a positive access outcome — NICE recommended budesonide as
Link to the full report here 1. Executive Summary MARA Rating has completed a formal surveillance review of CagriSema (cagrilintide + semaglutide) following publication of Phase 3 head-to-head results versus
Executive Summary In February 2026, MARA published 37 rating actions. The month was notable not only for volume, but for compression of the rating profile into the lower-middle bands. One
MARA rated lecanemab (Leqembi) B++ (Marginal) before G-BA published Beschluss 7692 on 19 February 2026. The B++ grade correctly identified the marginal and uncertain zone — G-BA’s outcome of kein
MARA rated nivolumab (Opdivo) A (Strong) before NICE published TA1127 on 4 February 2026, recommending the drug for neoadjuvant plus adjuvant treatment of resectable NSCLC without EGFR or ALK alterations.
Executive Summary In January 2026, MARA issued nine initial reimbursement risk assessments across cardiology, infectious disease, neurology, oncology, obesity, and immunology. The monthly profile was concentrated in the middle of
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split: